January 27, 2021
JAMA Network Open

Ruxolitinib for the Treatment of Steroid-Refractory Chronic Graft-vs-Host Disease—Another Hopeful Step Forward

 
AccessHope’s Vice President and Executive Clinical Director Joseph Alvarnas, MD, published a study in JAMA Network Open highlighting the use of a new treatment for the potentially life-ending chronic graft-vs-host disease (cGVHD) resulting from allogeneic hematopoietic stem cell transplantation (HSCT). The study progressively found that integrating evidence-based advances in the multidisciplinary care management of patients with cGVHD by a coordinated expert care team may lead to more-effective, personalized care solutions for this unique population.
 

Read Full Article Here

Previous

Next

Get started with AccessHope today

AccessHope’s team of specialists is ready to help plan the best suite of cancer support services for your employees.

Get started